Postdoctoral positions are available immediately to investigate mechanisms of target organ metastatic specificity, notably to brain. Specifically, unique scientific opportunities are presented for deciphering the biology and therapeutic utilities of Circulating Tumor Cells (CTCs) directly isolated and characterized from cancer patients - “seeds" of fatal metastatic disease. Positions relate to highly relevant and innovative programs of translational cancer biology using cutting-edge concepts and technologies.
Postdoctoral Fellows will be responsible implementing programs in the cell, molecular and translational biology of CTC metastatic specificity interplaying with dormancy and quiescence; involving the use of human CTCs/cell lines, pre-clinical CDX models and clinical samples reflective of disease status. Ph.D. is required. Extensive state-of-the-art CTC platforms, technologies and know-how are available in a well-funded and well-run laboratory.
Candidates must possess:
Salary and benefits are competitive and commensurate with research experience and background they are based upon the NIH Ruth Kirschenstein Postdoctoral Fellow Scale. Please send inquiries, including a Curriculum Vitae, and arrange for three letters of References (e-mails are OK) to be sent to:
Dario Marchetti, PhD
Professor, Division of Molecular Medicine
Department of Internal Medicine
UNM Comprehensive Cancer Center
Phone: (505) 272-7937
The University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius. One of the premier cancer centers nationwide, the UNM CCC has more than 125 board-certified oncology physicians, forming New Mexico’s largest cancer care team. It treats about 60 percent of adults and virtually all the children in New Mexico diagnosed with cancer — more than 10,000 people— from every county in the state in more than 135,000 clinic visits each year. Through its partnership with the New Mexico Cancer Care Alliance, an “exemplary national model for cancer health care delivery,” the UNM CCC offers access to more than 175 clinical trials to New Mexicans in every part of the state. Annual research funding of almost $60 million supports the UNM CCC’s 130 cancer scientists. Working with partners at Los Alamos and Sandia National Laboratories, Lovelace Respiratory Research Institute, and New Mexico State University, they have developed new diagnostics and drugs for leukemia, breast cancer, ovarian cancer, prostate cancer, liver and pancreatic cancer, brain cancer, and melanoma. Learn more at www.cancer.unm.edu.
Tags: UNMCC Postdocs